Caligan Partners Lp Buys 5,300 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Caligan Partners Lp bought 5,300 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average cost of $59.98 per share, for a total transaction of $317,894.00. Following the completion of the acquisition, the director directly owned 8,138,951 shares of the company’s stock, valued at $488,174,280.98. This trade represents a 0.07% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Liquidia Stock Performance

Shares of NASDAQ:LQDA traded up $1.79 on Wednesday, reaching $61.77. 1,754,852 shares of the company’s stock were exchanged, compared to its average volume of 1,557,702. The firm has a market capitalization of $5.49 billion, a price-to-earnings ratio of 441.25 and a beta of 0.41. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $62.17. The business’s 50-day moving average is $41.15 and its two-hundred day moving average is $36.81. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. As a group, equities research analysts forecast that Liquidia Corporation will post 2.97 EPS for the current year.

Analyst Ratings Changes

LQDA has been the topic of a number of analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. BTIG Research increased their price objective on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Oppenheimer increased their price objective on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a report on Thursday, March 12th. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Institutional Trading of Liquidia

A number of large investors have recently modified their holdings of LQDA. Federated Hermes Inc. bought a new position in Liquidia in the 3rd quarter valued at about $7,290,000. Caprock Group LLC bought a new position in Liquidia in the 3rd quarter valued at about $37,114,000. Apis Capital Advisors LLC bought a new position in Liquidia in the 3rd quarter valued at about $9,569,000. Farallon Capital Management LLC grew its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).